NBIX Neurocrine Biosciences Inc
XNAS
168.21
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NBIX
$168.21
—
What changed
Recent filings, trades and movesKey stats
$168.21
- 52-Week Range
- $122.14 – $186.12
- YTD
- +19.64%
- IV Rank (30D)
- 30.4
- Straddle Price
- $13.90
- P/C Vol Ratio
- 0.33
- Market Cap
- $16.7B
- Open
- $166.66
- Day Range
- $162.99 – $168.58
- Volume
- 762,913
- Prev Close
- $164.63
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.63 |
| Cost of Equity (CAPM) | 8.07% (VRP-adj) |
| WACC | 8.21% |
| Volatility Risk Premium | +12.0pp (IV − HV30) |
| Effective Tax Rate | 24.6% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 15 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.0B |
| Return on Equity (TTM) | 18.1% |
| Book / Price | 22.4% |
| Gross Margin (TTM) | 97.8% |
| FCF Margin (TTM) | 28.1% |
| Debt / Equity | 0.00 |
| Quality Score | 6/6 — compounder (15y DCF) |
| Market-Implied Growth | +1.0% (reverse-DCF on current price) |
| SMA 50 | $147.22 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $146.09 |
| Bollinger Width / SMA20 | 26.4% (drives anchor stability) |
| Net Debt | $-0.6B |
| Market Cap | $17B |
Peers used for multiples: ABBV, AMGN, BIIB, DFTX, EXEL, GILD, REGN, VRTX
Blended Fair Value
$527.39
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $1378.92 | 28% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $226.50 | 13% | median 30.6× · 6 peers |
| Peer EV/EBITDA | $199.11 | 13% | median 18.6× · 7 peers |
| Peer P/B | $242.60 | 3% | median 6.6× · 7 peers |
| Peer P/S | $259.72 | 8% | median 6.7× · 7 peers |
| Market Anchor (SMA50) | $147.22 | 10% | stability 18% (BB-width) |
| Options Expected (B-L 30d) | $165.09 | 25% | 18 strikes · skew +0.70 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $16.7B
- Employees
- 2,500
- List Date
- 1996-05-23
- CIK
- 0000914475
- Last Earnings
- Nov 2 after close · +13.4% vs ±10.3% expected
- Next Earnings
- ~Feb 10, 2027 (estimated)
- Headquarters
- San Diego, CA
- Homepage
- https://www.neurocrine.com
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, includ…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 14.48% | -10.68% | -7.62% | 6.10% | 10.13% | -3.23% | 1.53% |
| Feb | 3.29% | 13.44% | -6.46% | -8.46% | -20.91% | -3.91% | -3.84% |
| Mar | -11.13% | 2.02% | -0.03% | 5.04% | -3.39% | -0.48% | -1.33% |
| Apr | -3.76% | -5.80% | 0.18% | -2.72% | 0.64% | -0.67% | -2.02% |
| May | 2.77% | 2.49% | -13.93% | -5.33% | 15.41% | 20.12% | 3.59% |
| Jun | 2.55% | 5.10% | 3.41% | -1.61% | 0.91% | 4.68% | 2.51% |
| Jul | -4.36% | -5.16% | 7.84% | 1.04% | 0.18% | -0.80% | -0.21% |
| Aug | -0.74% | 13.69% | 5.27% | -17.04% | 8.29% | -7.34% | 0.35% |
| Sep | 0.33% | 0.55% | 1.69% | -7.90% | -1.09% | -9.52% | -2.66% |
| Oct | 3.89% | 7.87% | -0.76% | 5.36% | 4.53% | 3.83% | 4.12% |
| Nov | -21.62% | 6.45% | 4.53% | 3.71% | 7.19% | 15.91%* | 2.70% |
| Dec | 5.42% | -5.44% | 12.50% | 8.43% | -6.00% | -- | 2.98% |
| Total | -12.85% | 23.48% | 3.77% | -15.45% | 11.46% | 15.69% | 4.35% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $147.44
SMA 50: $147.50
SMA 200: $148.18
Current: $168.35
EMA 12: $155.85
EMA 26: $150.55
MACD: 5.3025 | Signal: 2.9222
BULLISH
ADX (14): 28.06
TREND
+DI: 35.39
−DI: 12.56
Momentum Oscillators
RSI (14): 71.97
OVERBOUGHT
Stoch %K: 84.04
Stoch %D: 82.93
Williams %R: -4.08
Volume & Volatility
BB Upper: $168.88
BB Lower: $126.00
NEUTRAL
OBV: 35,073,025
Vol SMA 20: 1,439,248
Vol ROC: -40.86%
ATR: $5.47
True Range: $5.59
HV 20: 53.6%
HV 30: 45.7%
HV 60: 36.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before NBIX’s Nov 2 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Positive news sentiment from recent headlines
- Low volatility relative to market
- Technical indicators showing neutral momentum
Primary Risks:
- Bearish MACD signal and weak trend indicators
- Potential for a pullback or consolidation phase
Investment Thesis: NBIX has been trending sideways, with positive news flow supporting the stock. However, technical signals indicate a lack of clear direction, making it challenging to take a strong bullish or bearish stance. A breakout above $162.08 or below $149.14 could trigger more significant price movements.
Recent News Sentiment Impact: The recent headlines have been overwhelmingly positive, with Nxera Pharma's partner Neurocrine Biosciences receiving IND acceptance from the FDA for Phase 2 study of NBI-1117567 for Alzheimer's cognition. This news has contributed to the stock's neutral sentiment and moderate price movement.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): BEARISH
- Long-term (3-12 months): NEUTRAL
Support/Resistance Levels: The key price levels to monitor are the SMA 20 ($155.61), SMA 50 ($165.88), and Bollinger Bands Upper ($162.08).
Momentum Signals:
- RSI: 44.05 (NEUTRAL)
- MACD: -2.38 / Signal: 0.83 / Histogram: -3.21 (BEARISH)
- Bollinger Bands position: NEUTRAL
Volume Analysis: The volume has been trending downward, with the Volume Rate of Change indicating a decline in buying interest.
News & Sentiment Analysis
Recent Headlines Summary: The headlines have been primarily positive, highlighting Nxera Pharma's operational highlights and consolidated results, as well as partner Neurocrine Biosciences' progress in their Phase 2 study.
Sentiment Assessment: The sentiment is NEUTRAL, with a slight bias towards positivity due to the recent news flow.
Catalyst Identification: The upcoming FDA approval for NBI-1117567 could be a significant catalyst, potentially driving price movements.
Market Narrative: The market narrative is that NBIX has been trending sideways, with positive news supporting the stock. The lack of clear direction in technical signals makes it challenging to take a strong stance.
Risk & Volatility Assessment
Risk Interpretation: Beta: 0.65 (LOW VOLATILITY)
Volatility Regime: Current vs historical volatility levels: LOW VOLATILITY
Options Market Signals: IV Rank: 5.3% (LOW), Current IV: 34.5%, Expected Move: $11.05, Volume Flow: 12 calls vs 39 puts
Downside Protection: The support level is at $155.61 (SMA 20), with potential for a pullback or consolidation phase.
Market Context & Positioning
Sector Performance: NBIX has been trending relatively stronger than the sector, with a sector-relative strength of +1.2%.
Institutional Activity: The institutional activity has been moderate, with no clear signs of increased interest.
Correlation Analysis: The stock moves relatively less than the market (R-squared interpretation), indicating low volatility.
Relative Valuation: NBIX is positioned within a trading range, with potential for breakout or consolidation.
Key Levels & Action Items
Critical Price Levels: Support: $155.61 (SMA 20), Resistance: $162.08 (Bollinger Bands Upper)
Breakout/Breakdown Levels: Bearish breakout below $149.14 could trigger significant price movements.
Time-Sensitive Catalysts: Upcoming FDA approval for NBI-1117567
Risk Management: Stop-loss levels and position sizing considerations should be based on the recent trend direction and volatility regime.
Please let me know if you need any further clarification or modifications to this report.
Generated
News
All NBIX news →
Record $1.1B revenue marks transformative quarter for diversified biotech.
Showing 1–10 of 17
Page 1 of 2
Earnings History
16 of 24 under expected move
Avg Expected Move
7.82%
Avg Actual Move
5.66%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-08 | After-Close | 7.28% | 1.58% | 0.22x | Within |
| 2021-05-05 | After-Close | 8.46% | 2.37% | 0.28x | Within |
| 2021-08-03 | After-Close | 7.57% | 4.61% | 0.61x | Within |
| 2021-11-01 | After-Close | 8.95% | 10.02% | 1.12x | Exceeded |
| 2022-01-06 | After-Close | 8.06% | 8.74% | 1.08x | Exceeded |
| 2022-05-04 | After-Close | 3.37% | 3.53% | 1.05x | Exceeded |
| 2022-08-04 | After-Close | 6.36% | 8.45% | 1.33x | Exceeded |
| 2022-11-01 | After-Close | 4.94% | 2.26% | 0.46x | Within |
| 2023-02-06 | After-Close | 4.11% | 1.14% | 0.28x | Within |
| 2023-05-03 | After-Close | 7.02% | 2.82% | 0.40x | Within |
| 2023-08-01 | After-Close | 4.86% | 0.68% | 0.14x | Within |
| 2023-10-31 | After-Close | 5.41% | 0.54% | 0.10x | Within |
| 2024-02-07 | After-Close | 5.03% | 1.37% | 0.27x | Within |
| 2024-05-01 | After-Close | 5.94% | 2.24% | 0.38x | Within |
| 2024-08-01 | After-Close | 13.74% | 0.01% | 0.00x | Within |
| 2024-10-30 | After-Close | 5.59% | 3.27% | 0.58x | Within |
| 2025-02-06 | After-Close | 12.79% | 18.53% | 1.45x | Exceeded |
| 2025-05-05 | After-Close | 10.71% | 8.36% | 0.78x | Within |
| 2025-07-30 | After-Close | 8.37% | 6.24% | 0.75x | Within |
| 2025-10-28 | After-Close | 12.30% | 6.35% | 0.52x | Within |
| 2026-02-11 | After-Close | 8.33% | 10.43% | 1.25x | Exceeded |
| 2026-05-05 | After-Close | 8.96% | 8.86% | 0.99x | Within |
| 2026-07-30 | After-Close | 9.22% | 10.08% | 1.09x | Exceeded |
| 2026-11-02 | After-Close | 10.32% | 13.42% | 1.30x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
NBIX Options Activity & IV Rank
NBIX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 31.7%
7-DTE IV: 33.7%
Expected Move: $13.90
7-DTE Move: $8.28
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 2,537
Put Volume: 825
P/C Volume: 0.325
BULLISH
Call OI: 15,463
Put OI: 7,360
P/C OI: 0.476
Total OI: 22,823
ATM Options Pricing
ATM Call: $5.75
ATM Put: $8.15
Call %: 3.4%
Put %: 4.8%
Chain Summary
Chain Volume: 3,362
Chain OI: 22,823
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 37th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
37%
vs own history
GEX tilt
+0.02
OI-weighted, today
Vanna tilt
+0.42
δ-sensitivity to IV
Charm tilt
-0.41
δ-decay vs time
Vanna tilt +0.42: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.41: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 39 ATM contracts, 6k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)23.4LowNov 9
IV Rank (30 DTE)30.4MediumNov 9
Straddle Price (30 DTE)$13.90Nov 9
Beta Analysis
Risk Metrics
Beta: 0.6555
Alpha: 8.02%
Correlation: 0.2572
R-Squared: 6.6%
Stock Volatility: 35.0%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own NBIX
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $393.7M | #28 of 3138 | -3.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $63.0M | #193 of 4729 | +32.4% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $34.7M | #117 of 997 | +38.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $2.0M | #2923 of 6285 | -79.5% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $2.0M | #2593 of 3716 | -99.1% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NBIX Institutional Ownership (13F)
Filings for 2026-06-30 · 362 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 104,200,000 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
11 filers$92.42M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | $33.71M | 36.47% | 2026-06-30 |
| 2 | Citigroup Inc. Custodian | $17.05M | 18.45% | 2026-09-30 |
| 3 | Susquehanna International Group, LLP Custodian | $15.07M | 16.30% | 2026-06-30 |
| 4 | JPMorgan Chase & Co Custodian | $8.84M | 9.57% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $5.70M | 6.16% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $4.61M | 4.99% | 2026-09-30 |
| 7 | Jane Street Group, LLC Custodian | $3.27M | 3.54% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $3.22M | 3.48% | 2026-09-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $623.58K | 0.67% | 2026-06-30 |
| 10 | Walleye Capital LLC | $269.66K | 0.29% | 2026-06-30 |
| 11 | Raiffeisen Bank International AG | $62.70K | 0.07% | 2026-09-30 |
12 filers$84.83M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $31.21M | 36.79% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $20.07M | 23.66% | 2026-06-30 |
| 3 | Citigroup Inc. Custodian | $13.39M | 15.78% | 2026-09-30 |
| 4 | JPMorgan Chase & Co Custodian | $5.10M | 6.01% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $4.53M | 5.34% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $3.35M | 3.95% | 2026-09-30 |
| 7 | Goldman Sachs Group Inc Custodian | $2.31M | 2.72% | 2026-06-30 |
| 8 | SIG BROKERAGE, LP | $1.67M | 1.97% | 2026-06-30 |
| 9 | Simplex Trading, LLC Custodian | $1.55M | 1.82% | 2026-09-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $977.50K | 1.15% | 2026-06-30 |
| 11 | Walleye Trading LLC | $623.58K | 0.74% | 2026-06-30 |
| 12 | Walleye Capital LLC | $50.56K | 0.06% | 2026-06-30 |
NBIX Insider Trading (Form 4)
Latest: 2026-11-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-05 | Eiry Roberts | Chief Medical Officer | Grant (A) | +9,820 opt | — | EDGAR | |
| 2026-11-03 | Kyle Gano | Chief Executive Officer | Mixed Exer +614 · Tax −332 |
+282 | $146.10 | -$48.5K | EDGAR |
| 2026-11-03 | George J Morrow | Director | Mixed Sell −15,000 · Exer +15,000 |
— | $104.69 | -$1.53M | EDGAR |
| 2026-09-15 | Matt Abernethy | Chief Financial Officer | Mixed Sell −2,311 · Tax −2,709 · Grant +5,020 |
— | $156.67 | -$786.5K | EDGAR |
| 2026-09-15 | Darin Lippoldt | Chief Legal Officer | Mixed Tax −2,419 · Grant +4,483 |
+2,064 | $156.22 | -$377.9K | EDGAR |
| 2026-09-15 | David W. Boyer | Chief Corp. Affairs Officer | Mixed Sell −826 · Tax −1,936 · Grant +3,587 |
+825 | $156.59 | -$432.5K | EDGAR |
| 2026-09-15 | Kevin Charles Gorman | Director | Mixed Grant +14,343 · Tax −7,839 |
+6,504 | $156.22 | -$1.22M | EDGAR |
| 2026-09-15 | Sanjay Chandru Keswani | Chief Medical Officer | Mixed Grant +3,914 · Tax −2,112 |
+1,802 | $156.22 | -$329.9K | EDGAR |
| 2026-09-15 | Julie Cooke | Chief Human Resources Officer | Mixed Grant +3,587 · Tax −1,936 |
+1,651 | $156.22 | -$302.4K | EDGAR |
| 2026-09-15 | Eric Benevich | Chief Commercial Officer | Mixed Tax −3,386 · Grant +6,275 |
+2,889 | $156.22 | -$529.0K | EDGAR |
| 2026-09-15 | Ingrid Delaet | Chief Regulatory Officer | Mixed Grant +4,483 · Tax −2,419 |
+2,064 | $156.22 | -$377.9K | EDGAR |
| 2026-09-15 | Kyle Gano | Chief Executive Officer | Mixed Grant +8,117 · Tax −4,380 |
+3,737 | $156.22 | -$684.2K | EDGAR |
| 2026-09-15 | Jude Onyia | Chief Scientific Officer | Mixed Grant +3,587 · Tax −1,936 |
+1,651 | $156.22 | -$302.4K | EDGAR |
| 2026-09-10 | Eric Benevich | Chief Commercial Officer | Mixed Exer +3,194 · Sell −2,154 |
+1,040 | $88.10 | -$194.9K | EDGAR |
| 2026-09-03 | Stephen A Sherwin | Director | Gift (G) | −1,000 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NBIX Insider Holdings
20 insiders · @ $168.35
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kevin Charles Gorman | Director | 517,797 | $87.17M | -$181.28M | 74 | 2026-09-15 |
| 2 | Kyle Gano | Chief Executive Officer | 155,010 | $26.10M | -$49.45M | 60 | 2026-11-03 |
| 3 | Gary A Lyons | Director | 122,141 | $20.56M | -$23.43M | 57 | 2026-05-29 |
| 4 | Eric Benevich | Chief Commercial Officer | 70,683 | $11.90M | -$47.31M | 47 | 2026-09-15 |
| 5 | Darin Lippoldt | Chief Legal Officer | 59,212 | $9.97M | -$35.08M | 65 | 2026-09-15 |
| 6 | Matt Abernethy | Chief Financial Officer | 47,828 | $8.05M | -$15.33M | 35 | 2026-09-15 |
| 7 | William H Rastetter | Director | 43,678 | $7.35M | -$13.07M | 27 | 2026-05-29 |
| 8 | Richard F Pops | Director | 37,798 | $6.36M | -$13.18M | 39 | 2026-05-29 |
| 9 | Eiry Roberts | Chief Medical Officer | 34,252 | $5.77M | -$21.23M | 36 | 2026-11-05 |
| 10 | Julie Cooke | Chief Human Resources Officer | 24,025 | $4.04M | -$20.50M | 39 | 2026-09-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NBIX Board & Officers
As of SEC filings through Nov 5, 2026Directors 11
- Gary A Lyons · on file since 2006
- Richard F Pops · on file since Jun 2006
- Stephen A Sherwin · on file since Jun 2006
- Kevin Charles Gorman · listed since Feb 2008
- William H Rastetter · since Feb 4, 2010
- George J Morrow · since Sep 30, 2015
- Leslie V Norwalk · since Sep 10, 2019
- Shalini Sharp · since Feb 1, 2020
- Johanna Mercier · since Apr 15, 2021
- Christine A Poon · since Jul 11, 2023
- Kyle Gano · listed since Nov 2024
Officers 11
- Kyle Gano · Chief Executive Officer · listed since Nov 2024
- Matt Abernethy · Chief Financial Officer · since Dec 1, 2017
- Darin Lippoldt · Chief Legal Officer · since Oct 31, 2014
- Eric Benevich · Chief Commercial Officer · listed since Jun 2015
- Eiry Roberts · Chief Medical Officer · since Jan 8, 2018
- Julie Cooke · Chief Human Resources Officer · since May 7, 2019
- Jude Onyia · Chief Scientific Officer · since Nov 29, 2021
- David W. Boyer · Chief Corp. Affairs Officer · since Feb 4, 2022
- Ingrid Delaet · Chief Regulatory Officer · since Feb 9, 2023
- Sanjay Chandru Keswani · Chief Medical Officer · since Jun 2, 2025
- Andrew Ratz · Chief Technical Operations Off · since Mar 15, 2026
Changes in the last 10 years (18)
| Mar 15, 2026 | Andrew Ratz became Chief Technical Operations Off |
| Jun 2, 2025 | Sanjay Chandru Keswani became Chief Medical Officer |
| Nov 1, 2024 | Kyle Gano listed as Chief Executive Officer (previously Chief Business Development Off) in SEC filings |
| Nov 1, 2024 | Kyle Gano first listed as a director in an SEC filing |
| May 28, 2024 | The company announced the departure of Kevin Charles Gorman as Chief Executive Officer in an SEC filing |
| Jul 11, 2023 | Christine A Poon became a director |
| Feb 9, 2023 | Ingrid Delaet became Chief Regulatory Officer |
| Feb 2, 2023 | Malcolm Lloyd-Smith listed as Chief Integration Officer (previously Chief Regulatory Officer) in SEC filings |
| Feb 4, 2022 | David W. Boyer became Chief Corp. Affairs Officer |
| Nov 29, 2021 | Jude Onyia became Chief Scientific Officer |
| Apr 15, 2021 | Johanna Mercier became a director |
| Feb 1, 2020 | Shalini Sharp became a director |
| Sep 10, 2019 | Leslie V Norwalk became a director |
| May 7, 2019 | Julie Cooke became Chief Human Resources Officer |
| Jan 8, 2018 | Eiry Roberts became Chief Medical Officer |
| Dec 1, 2017 | Matt Abernethy became Chief Financial Officer |
| Jan 12, 2017 | Kevin Charles Gorman listed as Chief Executive Officer (previously President and CEO) in SEC filings |
| Jan 9, 2017 | David-Alexandre C Gros became President & COO |
Not reported recently (9)
- Malcolm Lloyd-Smith · Last reported as Chief Integration Officer in an SEC filing dated Feb 8, 2023
- Dimitri E. Grigoriadis · Last reported as Chief Research Officer in an SEC filing dated Feb 2, 2022
- Haig P. Bozigian · Last reported as Chief Development Officer in an SEC filing dated Mar 29, 2021
- Alfred Sandrock · Last reported as a director in an SEC filing dated May 23, 2019
- Corinne H Nevinny · Last reported as a director in an SEC filing dated May 25, 2018
- Christopher Flint OBrien · Last reported as Chief Medical Officer in an SEC filing dated Feb 7, 2018
- Joseph A Mollica · Last reported as a director in an SEC filing dated Jun 8, 2017
- Timothy P Coughlin · Last reported as Chief Financial Officer in an SEC filing dated Feb 8, 2017
- David-Alexandre C Gros · Last reported as President & COO in an SEC filing dated Feb 8, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
NBIX Proposed Insider Sales (Form 144)
Latest: 2026-11-02
? Form 144 Guide
Last 30d:
2 filings
· $2.2M notice value
· Last 90d:
5 filings
· $3.6M notice value
· 4 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
GEORGE MORROW (2, $2.2M) · DAVID WARREN BOYER (1, $736K) · MATTHEW C ABERNETHY (1, $361K) · ERIC BENEVICH (1, $334K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-02 | GEORGE MORROW | Director | 14,700 | $2.15M | 2026-11-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-30 | GEORGE MORROW | Director | 300 | $43.9K | 2026-10-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-14 | MATTHEW C ABERNETHY | Officer | 2,311 | $361.0K | 2026-09-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-14 | DAVID WARREN BOYER | Officer | 4,714 | $736.4K | 2026-09-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-09 | ERIC BENEVICH | Officer | 2,154 | $334.2K | 2026-09-09 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-10 | INGRID DELAET | Officer | 4,367 | $788.5K | 2026-07-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-09 | DARIN LIPPOLDT | Officer | 10,000 | $1.78M | 2026-07-09 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-07 | INGRID DELAET | Officer | 14,571 | $2.54M | 2026-07-07 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-29 | DARIN LIPPOLDT | Officer | 9,800 | $1.65M | 2026-06-29 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-26 | DARIN LIPPOLDT | Officer | 200 | $32.8K | 2026-06-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-02
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-02 | Earnings results | EDGAR |
| 2026-09-28 | Director or officer change | EDGAR |
| 2026-07-30 | Earnings results | EDGAR |
| 2026-05-28 | Director or officer change · Shareholder vote results | EDGAR |
| 2026-05-18 | Material agreement · Acquisition or sale completed · New debt obligation · Regulation FD disclosure | EDGAR |
| 2026-05-05 | Earnings results | EDGAR |
| 2026-04-06 | Material agreement | EDGAR |
| 2026-02-11 | Earnings results | EDGAR |
| 2025-11-24 | Director or officer change | EDGAR |
| 2025-10-28 | Earnings results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-11 | 0000914475-26-000007 | EDGAR |
| 2025-02-10 | 0000914475-25-000037 | EDGAR |
| 2024-02-09 | 0000914475-24-000054 | EDGAR |
| 2023-02-09 | 0000914475-23-000011 | EDGAR |
| 2022-02-11 | 0000914475-22-000013 | EDGAR |
| 2021-02-05 | 0000914475-21-000020 | EDGAR |
| 2020-02-07 | 0001564590-20-003773 | EDGAR |
| 2019-02-08 | 0001564590-19-002328 | EDGAR |
| 2018-02-13 | 0001193125-18-042794 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-02 | 0000914475-26-000054 | EDGAR |
| 2026-07-31 | 0000914475-26-000037 | EDGAR |
| 2026-05-05 | 0000914475-26-000026 | EDGAR |
| 2025-10-28 | 0000914475-25-000181 | EDGAR |
| 2025-07-30 | 0000914475-25-000158 | EDGAR |
| 2025-05-05 | 0000914475-25-000100 | EDGAR |
| 2024-10-30 | 0000914475-24-000211 | EDGAR |
| 2024-08-01 | 0000914475-24-000181 | EDGAR |
| 2024-05-01 | 0000914475-24-000117 | EDGAR |
| 2023-10-31 | 0000914475-23-000073 | EDGAR |
ETF Holders
230 ETFs hold NBIX
25 shown · $3.24B total exposure · 0.37% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.50% | $605.6M | $121.4B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.02% | $458.8M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.18% | $324.6M | — | 2026-09-30 |
| 4 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.41% | $180.5M | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.17% | $162.3M | — | 2026-09-30 |
| 6 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.57% | $157.4M | $10.0B | 2026-11-05 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 1.14% | $125.0M | $11.1B | 2026-11-06 |
| 8 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.48% | $124.0M | $25.6B | 2026-11-05 |
| 9 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.85% | $114.2M | $3.0B | 2026-11-06 |
| 10 | USMV iShares MSCI USA Min Vol Factor ETF | iShares (BlackRock) | 0.47% | $112.0M | $23.7B | 2026-11-06 |
| 11 | XMHQ Invesco S&P MidCap Quality ETF | Invesco | 1.90% | $107.5M | — | 2026-11-05 |
| 12 | IJK iShares S&P Mid-Cap 400 Growth ETF | iShares (BlackRock) | 1.00% | $102.1M | $10.2B | 2026-11-06 |
| 13 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.49% | $89.1M | $18.3B | 2026-11-05 |
| 14 | VFLO VictoryShares Free Cash Flow ETF | Nport | 1.04% | $80.4M | — | 2026-06-30 |
| 15 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.45% | $79.0M | $17.3B | 2026-11-06 |
| 16 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.12% | $69.6M | $56.9B | 2026-11-06 |
| 17 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.05% | $53.0M | $114.6B | 2026-11-06 |
| 18 | COWZ Pacer US Cash Cows 100 ETF | Nport | 0.25% | $47.2M | — | 2026-07-31 |
| 19 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.29% | $42.8M | — | 2026-08-31 |
| 20 | VHT Vanguard Health Care ETF | Vanguard | 0.19% | $41.4M | — | 2026-09-30 |
| 21 | SCHG Schwab U.S. Large-Cap Growth ETF | Nport | 0.06% | $37.5M | — | 2026-08-31 |
| 22 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.04% | $36.0M | — | 2026-11-05 |
| 23 | JGRO JPMorgan Active Growth ETF | JPMorgan | 0.36% | $32.2M | $9.0B | 2026-11-06 |
| 24 | DYNF iShares U.S. Equity Factor Rotation Active ETF | iShares (BlackRock) | 0.07% | $30.4M | $40.6B | 2026-11-06 |
| 25 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.34% | $29.0M | $8.6B | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
25.00
TTM Diluted EPS
$6.74
TTM Revenue
$3.70B
TTM Net Income
$702.50M
TTM Op. Cash Flow
$1.07B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $1.12B | $206.50M | $1.96 | $395.20M |
| Q2 '26 | 2026-06-30 | $959.00M | $144.40M | $1.39 | $136.40M |
| Q1 '26 | 2026-03-31 | $814.50M | $197.90M | $1.91 | $145.80M |
| Q4 '25 | 2025-12-31 | $805.50M | $153.70M | $1.48 | $388.40M |
| Q3 '25 | 2025-09-30 | $794.90M | $209.50M | $2.04 | $227.50M |
| Q2 '25 | 2025-06-30 | $687.50M | $107.50M | $1.06 | $102.00M |
| Q1 '25 | 2025-03-31 | $572.60M | $7.90M | $0.08 | $64.80M |
| Q4 '24 | 2024-12-31 | $627.70M | $103.10M | $1.00 | $242.50M |
| Q3 '24 | 2024-09-30 | $622.10M | $129.80M | $1.24 | $158.00M |
| Q2 '24 | 2024-06-30 | $590.20M | $65.00M | $0.63 | $64.60M |
| Q1 '24 | 2024-03-31 | $515.30M | $43.40M | $0.42 | $130.30M |
| Q4 '23 | 2023-12-31 | $515.20M | $147.70M | $1.46 | $123.50M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-02
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
25.00
P/B
4.71
P/S
5.15
EV/EBITDA
20.37
EV/Sales
5.05
ROE
19.1%
ROA
13.2%
Div Yield
0.00%
FCF Yield
5.17%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$17.38B
as of 2026-11-09
NBIX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ABBV ABBVIE INC. | $514.9B | 50.5 | +10.7% | +27.9% | 34 |
| AMGN Amgen Inc | $249.0B | 26.9 | +8.2% | +41.6% | 33 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.4% | 49 |
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.6% | 63 |
| REGN Regeneron Pharmaceuticals Inc | $93.6B | 20.5 | +18.6% | +19.5% | 57 |
| BIIB Biogen Inc. Common Stock | $36.7B | 110.3 | +2.3% | +45.1% | 100 |
| EXEL Exelixis Inc | $17.0B | 21.5 | +9.1% | +64.8% | 37 |
| NBIX Neurocrine Biosciences Inc | $16.7B | 25.0 | +38.0% | +19.7% | 30 |
| DFTX Definium Therapeutics, Inc. Common Share | $4.5B | — | — | +128.3% | 24 |
| Peer median | $116.1B | 31.1 | +9.1% | +40.5% | 43 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.45M
SI % of Float
6.62%
Days to Cover
4.54
Short Vol Ratio
50.1%
Free Float
97.42M
Float %
95.8%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24